In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson ...

Illumina lowered its annual financial forecast and says it plans to cut about $100 million in costs after China banned imports of its gene sequencers last week. The San Diego maker of gene-sequencing ...

Thaysen has had to deal with orchestrating Illumina’s comeback strategy and the loose ends related to unwinding the company’s ...

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition and innovation in the US.

According to the decision of the EU's Court of Justice in Luxembourg, the European Commission had no right to block the acquisition of Grail Inc. by Illumina Inc. for $7 billion. This is stated in the ...

Grail (NASDAQ:GRAL) noted that more than 500K providers used the Quest (DGX) system last year. Illumina (ILMN) spun off Grail (GRAL) in June after being told by regulators to unwind a merger with ...

Reflects impairment of the goodwill and intangible assets recognized as a result of Illumina's acquisition of the Company in August 2021 ("the Acquisition"). Represents legal and professional ...

La empresa local de secuenciación genética citó ahorros de costos para alinearse con su futura estrategia comercial.

HSBC downgraded Illumina Inc (NASDAQ:ILMN) to “Hold” from “Buy” and slashed its price target to $100 from $190, citing new headwinds from China, potential U.S. research funding cuts, and rising ...

"Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today," said Ankur Dhingra, CFO of Illumina. "We will ...